Q1 Earnings Estimate for TARS Issued By William Blair

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities researchers at William Blair issued their Q1 2026 earnings per share estimates for Tarsus Pharmaceuticals in a research report issued on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown anticipates that the company will post earnings of ($0.06) per share for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at $0.32 EPS, Q3 2026 earnings at $0.56 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $1.62 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. The firm had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

A number of other brokerages have also recently issued reports on TARS. Guggenheim reissued a “buy” rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday. HC Wainwright reissued a “buy” rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday. Barclays cut their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating for the company in a research report on Wednesday. The Goldman Sachs Group upped their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. Finally, Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Stock Performance

Shares of TARS opened at $43.55 on Thursday. The firm has a market cap of $1.66 billion, a PE ratio of -11.43 and a beta of 1.01. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. The stock’s fifty day moving average price is $51.14 and its two-hundred day moving average price is $43.00.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Creative Planning bought a new stake in Tarsus Pharmaceuticals during the third quarter valued at approximately $362,000. China Universal Asset Management Co. Ltd. grew its position in Tarsus Pharmaceuticals by 64.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock worth $241,000 after acquiring an additional 2,879 shares in the last quarter. Emerald Mutual Fund Advisers Trust bought a new position in Tarsus Pharmaceuticals in the third quarter valued at $3,608,000. Harbor Capital Advisors Inc. increased its stake in Tarsus Pharmaceuticals by 57.5% in the third quarter. Harbor Capital Advisors Inc. now owns 18,105 shares of the company’s stock valued at $595,000 after acquiring an additional 6,612 shares during the last quarter. Finally, Emerald Advisers LLC purchased a new stake in Tarsus Pharmaceuticals during the third quarter valued at about $4,812,000. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.